Titan Pharmaceuticals (TTNP) Posts Earnings Results, Misses Estimates By $0.08 EPS
Titan Pharmaceuticals (NASDAQ:TTNP) posted its quarterly earnings results on Wednesday. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.08), Morningstar.com reports. The company had revenue of $0.95 million during the quarter. Titan Pharmaceuticals had a negative net margin of 136.32% and a negative return on equity of 355.20%.
Shares of TTNP stock traded down $0.17 during trading hours on Thursday, reaching $1.54. The company had a trading volume of 3,734 shares, compared to its average volume of 955,499. The company has a quick ratio of 3.49, a current ratio of 3.85 and a debt-to-equity ratio of 0.55. The company has a market cap of $22.92 million, a P/E ratio of -1.97 and a beta of 0.67. Titan Pharmaceuticals has a 1-year low of $1.03 and a 1-year high of $6.90.
Separately, ValuEngine raised Titan Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, February 2nd.
ILLEGAL ACTIVITY WARNING: “Titan Pharmaceuticals (TTNP) Posts Earnings Results, Misses Estimates By $0.08 EPS” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://theolympiareport.com/2019/05/16/titan-pharmaceuticals-ttnp-posts-earnings-results-misses-estimates-by-0-08-eps.html.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.
See Also: What is the 52-week high/low?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.